Clinical trial
A Phase 2a Multicenter Open-label Study to Evaluate the Safety and Efficacy of OnabotulinumtoxinA X in Subjects With Glabellar Lines
NCT05013424 is registered in ClinicalTrials.gov with Allergan as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2a Multicenter Open-label Study to Evaluate the Safety and Efficacy of OnabotulinumtoxinA X in Subjects With Glabellar Lines
- Lead sponsor
- Allergan
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 1, 2021
- Completion date
- July 7, 2022
- Enrollment
- 92 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.
glabellar lines